What Drugs Should You Not Take With Apixaban? The Complete Interaction Guide

Apixaban (Eliquis) is one of the most commonly prescribed anticoagulants in the United States, with over 10 million prescriptions filled annually. However, this direct Factor Xa inhibitor has significant interactions with multiple drug classes that can either increase bleeding risk or reduce its effectiveness — potentially increasing stroke and thromboembolic events by up to 50% in some cases. Understanding which medications absolutely cannot be combined with apixaban, and which require careful monitoring, is critical for patient safety.

What Is Apixaban and Why Drug Interactions Matter

Apixaban is an oral anticoagulant (blood thinner) used to prevent stroke in patients with atrial fibrillation, treat deep vein thrombosis and pulmonary embolism, and prevent blood clots after hip or knee replacement surgery. It works by directly inhibiting Factor Xa, a crucial enzyme in the coagulation cascade — essentially blocking one of the pathways your body uses to form clots.

The reason apixaban interacts with so many other drugs comes down to how your body processes it. Approximately 50% of apixaban is metabolized by the liver enzyme CYP3A4, and about 25% is eliminated via P-glycoprotein (a cellular transporter protein). Drugs that either induce these pathways (speed up apixaban elimination) or inhibit them (slow it down) can dramatically change apixaban blood levels. When levels drop too low, you lose anticoagulant protection. When they climb too high, bleeding risk escalates.

Clinical trial data illustrates the magnitude of this problem: patients taking apixaban with dual antiplatelet therapy experienced major bleeding rates of 5.9% per year compared to 2.5% with apixaban alone. That means for every 50 patients treated, an additional 3 to 4 will suffer a major bleed over one year.

Contraindicated Interactions: Drugs That Must Be Avoided

Four medications have been classified as contraindicated with apixaban by the FDA because they are potent, dual inhibitors of both CYP3A4 and P-glycoprotein. These drugs induce apixaban metabolism so aggressively that therapeutic blood levels cannot be maintained, even at maximum doses.

Rifampin (Tuberculosis Treatment)

Rifampin is one of the most powerful enzyme inducers known in clinical pharmacology. Concomitant use with apixaban can reduce apixaban exposure by up to 54%, according to FDA labeling. For a patient with atrial fibrillation taking apixaban 5 mg twice daily for stroke prevention, this reduction essentially creates a subtherapeutic state — the patient appears to be on anticoagulation but is not adequately protected. The absolute contraindication appears in the apixaban prescribing information, with no dose adjustment capable of overcoming the magnitude of induction.

Phenytoin and Carbamazepine (Antiepileptic Drugs)

Both phenytoin and carbamazepine are potent dual inducers used to control seizures. They increase apixaban metabolism through multiple pathways simultaneously. Patients with epilepsy who develop atrial fibrillation and require anticoagulation cannot safely use apixaban with these antiepileptics. Alternative antiepileptic agents that do not induce CYP3A4 (such as levetiracetam or valproic acid) may be considered, but switching seizure medications carries its own risks and requires careful neurological evaluation.

St. John's Wort (Herbal Supplement)

St. John's Wort is frequently used over-the-counter for depression or mood support, and patients often do not mention herbal supplements to their physicians. This plant-derived supplement is a potent CYP3A4 inducer, with the ability to reduce apixaban levels by approximately 40–50%. The FDA explicitly contraindicated this combination. Clinically, this interaction has caused thromboembolic events: cases in the FDA Adverse Event Reporting System (FAERS) describe patients who developed stroke or pulmonary embolism while on apixaban and an undisclosed St. John's Wort regimen.

Major Interactions: High Bleeding Risk and Severe Consequences

Dual Antiplatelet Therapy (Clopidogrel, Aspirin, or Both)

Clopidogrel and aspirin work through completely different mechanisms than apixaban. Clopidogrel blocks ADP-mediated platelet aggregation, while aspirin irreversibly inhibits platelet cyclooxygenase. When combined with apixaban's Factor Xa inhibition, these agents create additive or synergistic bleeding effects. The APPRAISE-2 trial, which studied apixaban combined with dual antiplatelet therapy in acute coronary syndrome, found major bleeding rates of 5.9% per year versus 2.5% with aspirin alone — a more than 2-fold increase. The trial was terminated early due to bleeding safety concerns. Current guidelines recommend avoiding this combination unless there is a compelling clinical reason (such as a recent coronary stent placement), in which case the combination is used only for a limited period with careful monitoring.

Warfarin (Another Anticoagulant)

Combining apixaban with warfarin adds no additional anticoagulant benefit and substantially increases bleeding risk. Data from clinical trials show that concomitant warfarin use increases major bleeding from 2.7% to 4.6% per year — a 70% relative increase. This combination has no clinical indication; if anticoagulation is needed, one agent should be chosen, not both. However, brief overlap (5–7 days) during transition between warfarin and apixaban is sometimes unavoidable and is managed by careful INR monitoring.

Unfractionated Heparin and Low-Molecular-Weight Heparin (LMWH)

Heparin compounds are potent anticoagulants used acutely in hospital settings. Combining heparin with apixaban creates dual anticoagulation through different mechanisms: heparin activates antithrombin, while apixaban directly inhibits Factor Xa. This combination is reserved for specific scenarios, such as bridging a patient from warfarin to apixaban or managing acute thrombosis. When both drugs are used together, it is done intentionally in controlled settings with careful monitoring for bleeding and with one drug discontinued as soon as clinically appropriate.

Strong CYP3A4 and P-Glycoprotein Inhibitors: Ketoconazole and Itraconazole

Azole antifungal agents (ketoconazole and itraconazole) powerfully inhibit both CYP3A4 and P-glycoprotein, slowing apixaban elimination. Studies show ketoconazole increases apixaban plasma concentrations by approximately 99% (nearly doubling them). Itraconazole produces similar increases. The FDA prescribing information explicitly states that apixaban dose should be reduced by 50% (e.g., from 5 mg to 2.5 mg twice daily) if concomitant use with ketoconazole or itraconazole is necessary. For severe systemic fungal infections, apixaban may need to be temporarily discontinued in favor of a parenteral anticoagulant, depending on the clinical context.

Pharmacological Mechanisms Behind Apixaban Interactions

Apixaban's interactions operate through two main pharmacokinetic pathways:

• CYP3A4 Metabolism: Approximately 50% of apixaban is cleared by hepatic CYP3A4 enzyme. Drugs that induce CYP3A4 (rifampin, phenytoin, carbamazepine, St. John's Wort) accelerate apixaban breakdown, lowering blood levels and reducing anticoagulant effect. Drugs that inhibit CYP3A4 (ketoconazole, itraconazole, certain protease inhibitors) slow metabolism, raising apixaban levels and increasing bleeding risk.
• P-Glycoprotein Transport: Approximately 25% of apixaban is eliminated via P-glycoprotein, an efflux transporter in the intestine and blood-brain barrier. The same inducers and inhibitors that affect CYP3A4 typically affect P-glycoprotein as well, making the interaction effect bidirectional and compounded.

Pharmacodynamic interactions (such as with antiplatelet drugs or other anticoagulants) work through a different mechanism: multiple anticoagulant or antiplatelet agents acting on the same target (the coagulation cascade) create redundant or excessive inhibition, pushing the bleeding risk above a clinically acceptable threshold.

Clinical Scenarios: Real-World Management

Scenario 1: A 72-Year-Old with Atrial Fibrillation and Tuberculosis

A 72-year-old woman with newly diagnosed atrial fibrillation (CHA2DS2-VASc score = 4, indicating high stroke risk) is prescribed apixaban 5 mg twice daily for stroke prevention. Two weeks later, she is diagnosed with pulmonary tuberculosis and her physician initiates standard four-drug therapy: isoniazid, rifampin, ethambutol, and pyrazinamide.

The Problem: Rifampin is present in the regimen, and it absolutely contradicts apixaban use. If the two drugs remain combined, apixaban levels will drop by ~54%, leaving the patient with negligible anticoagulation despite appearing to be on therapy.

Management: The physician must choose one of the following: (1) Switch apixaban to an anticoagulant not affected by rifampin, such as warfarin (though warfarin levels will also be affected by rifampin, requiring INR-based dosing and more frequent monitoring), or (2) Use an alternative tuberculosis regimen that does not include rifampin (such as moxifloxacin-based therapy), though this is less effective and not standard. Most commonly, the patient is converted to warfarin during tuberculosis treatment, with intensive INR monitoring (target INR 2–3), and apixaban is restarted once tuberculosis therapy is complete and rifampin has been cleared (allowing 2–3 weeks for enzyme induction to reverse).

Scenario 2: A 68-Year-Old Post-Acute Coronary Syndrome on Dual Antiplatelet Therapy

A 68-year-old man suffered an acute myocardial infarction (MI) and received a drug-eluting stent. He is discharged on dual antiplatelet therapy: aspirin 81 mg daily and clopidogrel 75 mg daily. Six months after the MI, he develops atrial fibrillation. His cardiologist and nephrologist assess him: he has a CHA2DS2-VASc score of 3 (indicating moderate stroke risk) and a HAS-BLED bleeding risk score of 2 (low-to-moderate bleeding risk). His ejection fraction has recovered to 50%.

The Question: Should apixaban be added to his dual antiplatelet regimen?

Management: Guidelines and trial data support triple therapy (apixaban + aspirin + clopidogrel) for only 1 month after the acute event, then de-escalation to apixaban + aspirin for 12 months, then apixaban monotherapy thereafter. Since this patient is 6 months post-MI and his anatomy no longer requires aggressive antiplatelet therapy, the cardiologist, in consultation with the nephrologist, decides to discontinue clopidogrel and continue aspirin 81 mg with newly initiated apixaban 5 mg twice daily. The patient is counseled on bleeding signs (dark stools, persistent bruising, unusual nosebleeds) and is advised to avoid NSAIDs, which would further elevate bleeding risk. He is scheduled for follow-up in 2 weeks to assess for bleeding and confirm tolerability.

Major Interactions: Quick Reference

• Rifampin (Contraindicated): Reduces apixaban exposure by 54%. Absolute contraindication — do not use together.
• Phenytoin (Contraindicated): Potent CYP3A4 inducer. Absolute contraindication — do not use together.
• Carbamazepine (Contraindicated): Potent CYP3A4 inducer. Absolute contraindication — do not use together.
• St. John's Wort (Contraindicated): CYP3A4 inducer available over-the-counter. Absolute contraindication — do not use together.
• Clopidogrel (Major): Dual antiplatelet therapy increases major bleeding to 5.9% per year. Avoid unless short-term urgent indication (e.g., recent stent).
• Aspirin (Major): Increases bleeding risk 2–3 fold. Use only when specifically indicated (post-MI, stroke prevention); patient counseling essential.
• Warfarin (Major): Increases major bleeding to 4.6% per year. Do not combine; transition with brief overlap only.
• Unfractionated Heparin / LMWH (Major): Dual anticoagulation increases bleeding. Use only in acute settings with planned discontinuation of one agent.
• Ketoconazole (Major): Increases apixaban levels by ~99%. Reduce apixaban dose to 50% (e.g., 2.5 mg twice daily) if concomitant use necessary.
• Itraconazole (Major): Increases apixaban levels significantly. Reduce apixaban dose by 50% or avoid concomitant use; discontinue itraconazole at least 2 weeks before resuming apixaban alone.

Moderate Interactions and Special Populations

Beyond the contraindicated and major interactions, several drug classes warrant caution:

NSAIDs (Ibuprofen, Naproxen, Meloxicam): Non-steroidal anti-inflammatory drugs increase gastrointestinal bleeding risk and reduce renal blood flow, which can impair apixaban clearance. NSAIDs are not absolutely contraindicated but should be used at the lowest effective dose for the shortest duration, with gastroprotection (a proton pump inhibitor) considered. Acetaminophen is preferred for mild-to-moderate pain in patients on apixaban.

Antiplatelets Other Than Aspirin and Clopidogrel (Ticagrelor, Prasugrel): Newer P2Y12 inhibitors carry similar bleeding risk as clopidogrel when combined with apixaban. Use only in acute coronary syndrome with planned short-term overlap.

Direct-Acting Antivirals for Hepatitis C (Ritonavir-Boosted Protease Inhibitors): Some older antiretroviral regimens contain strong CYP3A4 inhibitors (ritonavir). Modern regimens are better tolerated and less interactive, but apixaban dose reduction may be needed with certain combinations.

Moderate CYP3A4 Inhibitors (Diltiazem, Verapamil, Erythromycin): These are not contraindicated and do not require automatic dose adjustment. However, they modestly increase apixaban levels (approximately 10–30% increase in exposure). Patients should be monitored clinically for signs of over-anticoagulation (bleeding). If a patient on apixaban must start a moderate CYP3A4 inhibitor, no immediate dose change is needed, but the patient should be counseled on bleeding signs and followed closely.

What Patients Should Tell Their Doctor

Patients on apixaban should provide their healthcare team with a comprehensive medication list before starting any new drug, including:

• All prescription medications, including antiepileptic drugs, antifungals, antibiotics, antiretrovirals, and cardiovascular medications
• All over-the-counter medications, particularly NSAIDs, cold and allergy remedies, and pain relievers
• All dietary supplements and herbal products, especially St. John's Wort, ginkgo biloba, and ginger (which have mild antiplatelet effects)
• Any recent changes to doses or discontinuations of chronic medications
• New diagnoses requiring acute treatment (infection, pain, inflammation), which often necessitate medications that interact with apixaban

Patients should also inform their doctor if they notice signs of bleeding (persistent nosebleeds, blood in urine or stool, unusual bruising, heavy menstrual bleeding) or signs of clotting (sudden leg swelling, chest pain, shortness of breath, sudden weakness), as either could indicate an interaction or a dose mismatch.

Key Takeaways

• Apixaban has four absolutely contraindicated drugs: rifampin, phenytoin, carbamazepine, and St. John's Wort. These dual CYP3A4 and P-glycoprotein inducers reduce apixaban levels by 40–54%, eliminating anticoagulant protection and increasing stroke risk.
• Antiplatelet drugs (clopidogrel, aspirin) and other anticoagulants (warfarin, heparin) dramatically increase bleeding risk when combined with apixaban. Major bleeding rates climb from 2.5% to 4.6–5.9% per year. Combination therapy is reserved for specific acute scenarios with planned short-term use.
• Strong CYP3A4 and P-glycoprotein inhibitors (ketoconazole, itraconazole) increase apixaban levels by up to 99%, requiring a 50% dose reduction. Always communicate with your pharmacist and physician if starting any new antifungal agent while on apixaban.
• Patients should disclose all medications, supplements, and herbal products to their healthcare provider before starting apixaban or making any medication changes. Over-the-counter supplements like St. John's Wort are common culprits in unrecognized interactions.
• NSAIDs, moderate CYP3A4 inhibitors (diltiazem, verapamil), and certain antibiotics are not contraindicated but require clinical monitoring. Use the lowest effective dose for the shortest period, and report any signs of bleeding or clotting to your doctor immediately.

Sources

• FDA Drug Labeling for Apixaban (Eliquis): https://open.fda.gov (OpenFDA database)
• FDA Prescribing Information for Apixaban (Eliquis): Accessed via DailyMed, National Library of Medicine, https://dailymed.nlm.nih.gov
• Apixaban Clinical Efficacy and Safety: Alexander JH, et al. ARISTOTLE Trial. N Engl J Med. 2011. PubMed PMID: 21830957
• Dual Antiplatelet Therapy with Apixaban: APPRAISE-2 Trial Steering Committee. N Engl J Med. 2013. (Trial terminated early due to bleeding)
• Drug Interaction Data: FDA Adverse Event Reporting System (FAERS), https://fis.fda.gov/sense/app/d10eg5jd3q
• CYP3A4 and P-Glycoprotein Metabolism: FDA Guidance for Industry on Drug Interactions, https://www.fda.gov/drugs/guidance-industry
• Antithrombotic Therapy Guidelines: American College of Chest Physicians (ACCP) Evidence-Based Clinical Practice Guidelines

Check Your Full Medication List for Interactions

Apixaban interactions extend beyond those listed here, and individual patient factors (age, kidney function, liver function, body weight) influence how your body handles this drug. If you are taking apixaban and have started, stopped, or changed any other medication, or if you are considering starting a new supplement or herbal product, enter your complete medication list into checkdruginteractions.com — the most comprehensive FDA-powered drug interaction checker available. Our database contains over 250,000 FDA drug labels and is updated continuously. This tool is free, confidential, and takes just a few minutes. Don't rely on memory alone: use checkdruginteractions.com to verify your medications before the next dose.

Related Drug Interactions

If you are researching apixaban interactions, you may also find these related resources helpful:

• Apixaban and Warfarin Interaction
• Apixaban and Aspirin Interaction
• Apixaban and Clopidogrel Interaction